Report Code: 12295 | Available Format: PDF | Pages: 190
Chapter 1. Research Scope
1.1. Research Objectives
1.2. Market Definition
1.3. Analysis Period
1.4. Market Size Breakdown by Segment
1.4.1. Market size breakdown, by offering
1.4.2. Market size breakdown, by technology
1.4.3. Market size breakdown, by application
1.4.4. Market size breakdown, by end user
1.4.5. Market size breakdown, by region
1.5. Market Data Reporting Unit
1.5.1. Value
1.6. Key Stakeholders
Chapter 2. Research Methodology
2.1. Secondary Research
2.1.1. Paid
2.1.2. Unpaid
2.1.3. P&S Intelligence database
2.2. Primary Research
2.3. Market Size Estimation
2.4. Data Triangulation
2.5. Currency Conversion Rates
2.6. Assumptions for the Study
2.7. Notes and Caveats
Chapter 3. Executive Summary
Chapter 4. Industry Outlook
4.1. Market Dynamics
4.1.1. Trends
4.1.2. Drivers
4.1.3. Restraints/challenges
4.1.4. Impact analysis of drivers/restraints
4.2. Impact of COVID-19
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining power of buyers
4.3.2. Bargaining power of suppliers
4.3.3. Threat of new entrants
4.3.4. Intensity of rivalry
4.3.5. Threat of substitutes
Chapter 5. Global Market
5.1. Overview
5.2. Market Revenue, by Offering (2017–2030)
5.3. Market Revenue, by Technology (2017–2030)
5.4. Market Revenue, by Application (2017–2030)
5.5. Market Revenue, by End User (2017–2030)
5.6. Market Revenue, by Region (2017–2030)
Chapter 6. North America Market
6.1. Overview
6.2. Market Revenue, by Offering (2017–2030)
6.3. Market Revenue, by Technology (2017–2030)
6.4. Market Revenue, by Application (2017–2030)
6.5. Market Revenue, by End User (2017–2030)
6.6. Market Revenue, by Country (2017–2030)
Chapter 7. Europe Market
7.1. Overview
7.2. Market Revenue, by Offering (2017–2030)
7.3. Market Revenue, by Technology (2017–2030)
7.4. Market Revenue, by Application (2017–2030)
7.5. Market Revenue, by End User (2017–2030)
7.6. Market Revenue, by Country (2017–2030)
Chapter 8. APAC Market
8.1. Overview
8.2. Market Revenue, by Offering (2017–2030)
8.3. Market Revenue, by Technology (2017–2030)
8.4. Market Revenue, by Application (2017–2030)
8.5. Market Revenue, by End User (2017–2030)
8.6. Market Revenue, by Country (2017–2030)
Chapter 9. LATAM Market
9.1. Overview
9.2. Market Revenue, by Offering (2017–2030)
9.3. Market Revenue, by Technology (2017–2030)
9.4. Market Revenue, by Application (2017–2030)
9.5. Market Revenue, by End User (2017–2030)
9.6. Market Revenue, by Country (2017–2030)
Chapter 10. MEA Market
10.1. Overview
10.2. Market Revenue, by Offering (2017–2030)
10.3. Market Revenue, by Technology (2017–2030)
10.4. Market Revenue, by Application (2017–2030)
10.5. Market Revenue, by End User (2017–2030)
10.6. Market Revenue, by Country (2017–2030)
Chapter 11. Competitive Landscape
11.1. List of Market Players and Their Offerings
11.2. Competitive Benchmarking of Key Players
11.3. Product Benchmarking of Key Players
11.4. Recent Strategic Developments
Chapter 12. Company Profiles
12.1. Thermo Fisher Scientific Inc.
12.1.1. Business overview
12.1.2. Product and service offerings
12.1.3. Key financial summary
12.2. F. Hoffmann-La Roche Ltd.
12.2.1. Business overview
12.2.2. Product and service offerings
12.2.3. Key financial summary
12.3. Myriad Genetics Inc.
12.3.1. Business overview
12.3.2. Product and service offerings
12.3.3. Key financial summary
12.4. Exact Sciences Corporation
12.4.1. Business overview
12.4.2. Product and service offerings
12.4.3. Key financial summary
12.5. Mesa Laboratories Inc.
12.5.1. Business overview
12.5.2. Product and service offerings
12.5.3. Key financial summary
12.6. Laboratory Corporation of America Holdings
12.6.1. Business overview
12.6.2. Product and service offerings
12.6.3. Key financial summary
12.7. Company 7
12.7.1. Business overview
12.7.2. Product and service offerings
12.7.3. Key financial summary
12.8. Company 8
12.8.1. Business overview
12.8.2. Product and service offerings
12.8.3. Key financial summary
12.9. Company 9
12.9.1. Business overview
12.9.2. Product and service offerings
12.9.3. Key financial summary
12.10. Company 10
12.10.1. Business overview
12.10.2. Product and service offerings
12.10.3. Key financial summary
12.11. Company 11
12.11.1. Business overview
12.11.2. Product and service offerings
12.11.3. Key financial summary
12.12. Company 12
12.12.1. Business overview
12.12.2. Product and service offerings
12.12.3. Key financial summary
12.13. Company 13
12.13.1. Business overview
12.13.2. Product and service offerings
12.13.3. Key financial summary
12.14. Company 14
12.14.1. Business overview
12.14.2. Product and service offerings
12.14.3. Key financial summary
12.15. Company 15
12.15.1. Business overview
12.15.2. Product and service offerings
12.15.3. Key financial summary
Chapter 13. Appendix
13.1. Abbreviations
13.2. Sources and References
13.3. Related Reports
LIST OF TABLES
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 3 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 4 GLOBAL PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2022)
TABLE 5 GLOBAL PHARMACOGENOMICS MARKET, BY OFFERING, $M (2023–2026)
TABLE 6 GLOBAL PHARMACOGENOMICS MARKET, BY OFFERING, $M (2027–2030)
TABLE 7 GLOBAL PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2017–2022)
TABLE 8 GLOBAL PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2023–2026)
TABLE 9 GLOBAL PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2027–2030)
TABLE 10 GLOBAL PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2017–2022)
TABLE 11 GLOBAL PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2023–2026)
TABLE 12 GLOBAL PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2027–2030)
TABLE 13 GLOBAL PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2022)
TABLE 14 GLOBAL PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2023–2026)
TABLE 15 GLOBAL PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2027–2030)
TABLE 16 GLOBAL PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2022)
TABLE 17 GLOBAL PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2023–2026)
TABLE 18 GLOBAL PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2027–2030)
TABLE 19 GLOBAL PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2022)
TABLE 20 GLOBAL PHARMACOGENOMICS MARKET, BY END USER, $M (2023–2026)
TABLE 21 GLOBAL PHARMACOGENOMICS MARKET, BY END USER, $M (2027–2030)
TABLE 22 GLOBAL PHARMACOGENOMICS MARKET, BY REGION, $M (2017–2022)
TABLE 23 GLOBAL PHARMACOGENOMICS MARKET, BY REGION, $M (2023–2026)
TABLE 24 GLOBAL PHARMACOGENOMICS MARKET, BY REGION, $M (2027–2030)
TABLE 25 NORTH AMERICA PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2022)
TABLE 26 NORTH AMERICA PHARMACOGENOMICS MARKET, BY OFFERING, $M (2023–2026)
TABLE 27 NORTH AMERICA PHARMACOGENOMICS MARKET, BY OFFERING, $M (2027–2030)
TABLE 28 NORTH AMERICA PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2017–2022)
TABLE 29 NORTH AMERICA PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2023–2026)
TABLE 30 NORTH AMERICA PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2027–2030)
TABLE 31 NORTH AMERICA PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2017–2022)
TABLE 32 NORTH AMERICA PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2023–2026)
TABLE 33 NORTH AMERICA PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2027–2030)
TABLE 34 NORTH AMERICA PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2022)
TABLE 35 NORTH AMERICA PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2023–2026)
TABLE 36 NORTH AMERICA PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2027–2030)
TABLE 37 NORTH AMERICA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2022)
TABLE 38 NORTH AMERICA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2023–2026)
TABLE 39 NORTH AMERICA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2027–2030)
TABLE 40 NORTH AMERICA PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2022)
TABLE 41 NORTH AMERICA PHARMACOGENOMICS MARKET, BY END USER, $M (2023–2026)
TABLE 42 NORTH AMERICA PHARMACOGENOMICS MARKET, BY END USER, $M (2027–2030)
TABLE 43 NORTH AMERICA PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2022)
TABLE 44 NORTH AMERICA PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2023–2026)
TABLE 45 NORTH AMERICA PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2027–2030)
TABLE 46 EUROPE PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2022)
TABLE 47 EUROPE PHARMACOGENOMICS MARKET, BY OFFERING, $M (2023–2026)
TABLE 48 EUROPE PHARMACOGENOMICS MARKET, BY OFFERING, $M (2027–2030)
TABLE 49 EUROPE PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2017–2022)
TABLE 50 EUROPE PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2023–2026)
TABLE 51 EUROPE PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2027–2030)
TABLE 52 EUROPE PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2017–2022)
TABLE 53 EUROPE PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2023–2026)
TABLE 54 EUROPE PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2027–2030)
TABLE 55 EUROPE PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2022)
TABLE 56 EUROPE PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2023–2026)
TABLE 57 EUROPE PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2027–2030)
TABLE 58 EUROPE PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2022)
TABLE 59 EUROPE PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2023–2026)
TABLE 60 EUROPE PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2027–2030)
TABLE 61 EUROPE PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2022)
TABLE 62 EUROPE PHARMACOGENOMICS MARKET, BY END USER, $M (2023–2026)
TABLE 63 EUROPE PHARMACOGENOMICS MARKET, BY END USER, $M (2027–2030)
TABLE 64 EUROPE PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2022)
TABLE 65 EUROPE PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2023–2026)
TABLE 66 EUROPE PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2027–2030)
TABLE 67 APAC PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2022)
TABLE 68 APAC PHARMACOGENOMICS MARKET, BY OFFERING, $M (2023–2026)
TABLE 69 APAC PHARMACOGENOMICS MARKET, BY OFFERING, $M (2027–2030)
TABLE 70 APAC PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2017–2022)
TABLE 71 APAC PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2023–2026)
TABLE 72 APAC PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2027–2030)
TABLE 73 APAC PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2017–2022)
TABLE 74 APAC PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2023–2026)
TABLE 75 APAC PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2027–2030)
TABLE 76 APAC PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2022)
TABLE 77 APAC PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2023–2026)
TABLE 78 APAC PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2027–2030)
TABLE 79 APAC PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2022)
TABLE 80 APAC PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2023–2026)
TABLE 81 APAC PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2027–2030)
TABLE 82 APAC PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2022)
TABLE 83 APAC PHARMACOGENOMICS MARKET, BY END USER, $M (2023–2026)
TABLE 84 APAC PHARMACOGENOMICS MARKET, BY END USER, $M (2027–2030)
TABLE 85 APAC PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2022)
TABLE 86 APAC PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2023–2026)
TABLE 87 APAC PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2027–2030)
TABLE 88 LATAM PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2022)
TABLE 89 LATAM PHARMACOGENOMICS MARKET, BY OFFERING, $M (2023–2026)
TABLE 90 LATAM PHARMACOGENOMICS MARKET, BY OFFERING, $M (2027–2030)
TABLE 91 LATAM PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2017–2022)
TABLE 92 LATAM PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2023–2026)
TABLE 93 LATAM PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2027–2030)
TABLE 94 LATAM PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2017–2022)
TABLE 95 LATAM PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2023–2026)
TABLE 96 LATAM PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2027–2030)
TABLE 97 LATAM PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2022)
TABLE 98 LATAM PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2023–2026)
TABLE 99 LATAM PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2027–2030)
TABLE 100 LATAM PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2022)
TABLE 101 LATAM PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2023–2026)
TABLE 102 LATAM PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2027–2030)
TABLE 103 LATAM PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2022)
TABLE 104 LATAM PHARMACOGENOMICS MARKET, BY END USER, $M (2023–2026)
TABLE 105 LATAM PHARMACOGENOMICS MARKET, BY END USER, $M (2027–2030)
TABLE 106 LATAM PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2022)
TABLE 107 LATAM PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2023–2026)
TABLE 108 LATAM PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2027–2030)
TABLE 109 MEA PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2022)
TABLE 110 MEA PHARMACOGENOMICS MARKET, BY OFFERING, $M (2023–2026)
TABLE 111 MEA PHARMACOGENOMICS MARKET, BY OFFERING, $M (2027–2030)
TABLE 112 MEA PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2017–2022)
TABLE 113 MEA PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2023–2026)
TABLE 114 MEA PHARMACOGENOMICS PRODUCT MARKET, BY TYPE, $M (2027–2030)
TABLE 115 MEA PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2017–2022)
TABLE 116 MEA PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2023–2026)
TABLE 117 MEA PHARMACOGENOMICS SERVICES MARKET, BY TYPE, $M (2027–2030)
TABLE 118 MEA PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2022)
TABLE 119 MEA PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2023–2026)
TABLE 120 MEA PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2027–2030)
TABLE 121 MEA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2022)
TABLE 122 MEA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2023–2026)
TABLE 123 MEA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2027–2030)
TABLE 124 MEA PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2022)
TABLE 125 MEA PHARMACOGENOMICS MARKET, BY END USER, $M (2023–2026)
TABLE 126 MEA PHARMACOGENOMICS MARKET, BY END USER, $M (2027–2030)
TABLE 127 MEA PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2022)
TABLE 128 MEA PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2023–2026)
TABLE 129 MEA PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2027–2030)
TABLE 130 COMPANY 1 – AT A GLANCE
TABLE 131 COMPANY 1 – KEY FINANCIAL SUMMARY
TABLE 132 COMPANY 2 – AT A GLANCE
TABLE 133 COMPANY 2 – KEY FINANCIAL SUMMARY
TABLE 134 COMPANY 3 – AT A GLANCE
TABLE 135 COMPANY 3 – KEY FINANCIAL SUMMARY
TABLE 136 COMPANY 4 – AT A GLANCE
TABLE 137 COMPANY 4 – KEY FINANCIAL SUMMARY
TABLE 138 COMPANY 5 – AT A GLANCE
TABLE 139 COMPANY 5 – KEY FINANCIAL SUMMARY
TABLE 140 COMPANY 6 – AT A GLANCE
TABLE 141 COMPANY 6 – KEY FINANCIAL SUMMARY
TABLE 142 COMPANY 7 – AT A GLANCE
TABLE 143 COMPANY 7 – KEY FINANCIAL SUMMARY
TABLE 144 COMPANY 8 – AT A GLANCE
TABLE 145 COMPANY 8 – KEY FINANCIAL SUMMARY
TABLE 146 COMPANY 9 – AT A GLANCE
TABLE 147 COMPANY 9 – KEY FINANCIAL SUMMARY
TABLE 148 COMPANY 10 – AT A GLANCE
TABLE 149 COMPANY 10 – KEY FINANCIAL SUMMARY
TABLE 150 COMPANY 11 – AT A GLANCE
TABLE 151 COMPANY 11 – KEY FINANCIAL SUMMARY
TABLE 152 COMPANY 12 – AT A GLANCE
TABLE 153 COMPANY 12 – KEY FINANCIAL SUMMARY
TABLE 154 COMPANY 13 – AT A GLANCE
TABLE 155 COMPANY 13 – KEY FINANCIAL SUMMARY
TABLE 156 COMPANY 14 – AT A GLANCE
TABLE 157 COMPANY 14 – KEY FINANCIAL SUMMARY
TABLE 158 COMPANY 15 – AT A GLANCE
TABLE 159 COMPANY 15 – KEY FINANCIAL SUMMARY
LIST OF FIGURES
FIG 1 MARKET SIZE BREAKDOWN BY SEGMENT
FIG 2 RESEARCH METHODOLOGY
FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY REGION
FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION
FIG 5 BREAKDOWN OF PRIMARY RESEARCH, BY COMPANY TYPE
FIG 6 DATA TRIANGULATION APPROACH
FIG 7 CURRENCY CONVERSION RATES FOR USD (2022)
FIG 8 GLOBAL PHARMACOGENOMICS MARKET SUMMARY
FIG 9 BARGAINING POWER OF BUYERS
FIG 10 BARGAINING POWER OF SUPPLIERS
FIG 11 INTENSITY OF RIVALRY
FIG 12 THREAT OF NEW ENTRANTS
FIG 13 THREAT OF SUBSTITUTES
FIG 14 GLOBAL PHARMACOGENOMICS MARKET SNAPSHOT
FIG 15 GLOBAL PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2030)
FIG 16 GLOBAL PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2030)
FIG 17 GLOBAL PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2030)
FIG 18 GLOBAL PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2030)
FIG 19 MAJOR WORLDWIDE MARKETS FOR PHARMACOGENOMICS SOLUTIONS, $M
FIG 20 NORTH AMERICA PHARMACOGENOMICS MARKET SNAPSHOT
FIG 21 NORTH AMERICA PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2030)
FIG 22 NORTH AMERICA PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2030)
FIG 23 NORTH AMERICA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2030)
FIG 24 NORTH AMERICA PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2030)
FIG 25 NORTH AMERICA PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2030)
FIG 26 EUROPE PHARMACOGENOMICS MARKET SNAPSHOT
FIG 27 EUROPE PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2030)
FIG 28 EUROPE PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2030)
FIG 29 EUROPE PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2030)
FIG 30 EUROPE PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2030)
FIG 31 EUROPE PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2030)
FIG 32 APAC PHARMACOGENOMICS MARKET SNAPSHOT
FIG 33 APAC PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2030)
FIG 34 APAC PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2030)
FIG 35 APAC PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2030)
FIG 36 APAC PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2030)
FIG 37 APAC PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2030)
FIG 38 LATAM PHARMACOGENOMICS MARKET SNAPSHOT
FIG 39 LATAM PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2030)
FIG 40 LATAM PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2030)
FIG 41 LATAM PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2030)
FIG 42 LATAM PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2030)
FIG 43 LATAM PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2030)
FIG 44 MEA PHARMACOGENOMICS MARKET SNAPSHOT
FIG 45 MEA PHARMACOGENOMICS MARKET, BY OFFERING, $M (2017–2030)
FIG 46 MEA PHARMACOGENOMICS MARKET, BY APPLICATION, $M (2017–2030)
FIG 47 MEA PHARMACOGENOMICS MARKET, BY TECHNOLOGY, $M (2017–2030)
FIG 48 MEA PHARMACOGENOMICS MARKET, BY END USER, $M (2017–2030)
FIG 49 MEA PHARMACOGENOMICS MARKET, BY COUNTRY, $M (2017–2030)
FIG 50 COMPANY 1 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 51 COMPANY 2 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 52 COMPANY 3 – REVENUE SPLIT BY SOURCE AND GEOGRAPHY (2022)
FIG 53 COMPANY 4 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 54 COMPANY 5 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 55 COMPANY 6 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 56 COMPANY 7 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 57 COMPANY 8 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 58 COMPANY 9 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 59 COMPANY 10 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 60 COMPANY 11 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 61 COMPANY 12 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 62 COMPANY 13 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 63 COMPANY 14 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
FIG 64 COMPANY 15 – REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2022)
Get a bespoke market intelligence solution
Want a report tailored exactly to your business strategy?
Request CustomizationWant an insight-rich discussion with the report author?
Speak to AnalystOur dedication to providing the most-accurate market information has earned us verification by Dun & Bradstreet (D&B). We strive for quality checking of the highest level to enable data-driven decision making for you
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
With 24/7 research support, we ensure that the wheels of your business never stop turning. Don’t let time stand in your way. Get all your queries answered with a simple phone call or email, as and when required
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws